查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1957203

失眠藥物治療市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物、療法、分銷管道、地區和競爭對手分類，2021-2031年

Insomnia Pharmacological Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug, By Treatment, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球失眠藥物治療市場預計將從 2025 年的 40.3 億美元成長到 2031 年的 56.3 億美元，複合年成長率為 5.73%。

此領域涵蓋多種處方藥和非處方藥，旨在促進入睡和維持睡眠，包括苯二氮平類藥物、非苯二氮平類藥物、Orexin受體拮抗劑和褪黑激素促效劑。推動該領域成長的主要因素是全球睡眠障礙的增加，這源於現代生活的壓力以及老齡化社會對晝夜節律紊亂的易感性。此外，醫療保健支出的增加以及人們對睡眠衛生在預防醫學中重要作用的認知不斷提高，也促進了該行業的持續成長。

市場概覽
預測期 2027-2031
市場規模：2025年 40.3億美元
市場規模：2031年 56.3億美元
複合年成長率：2026-2031年 5.73%
成長最快的細分市場 非處方助眠藥
最大的市場 北美洲

儘管市場呈現強勁成長趨勢，但長期使用鎮靜劑可能導致依賴，並引發安全隱患，這些都構成了市場面臨的重大障礙，因此需要更嚴格的監管，也造成了患者的抵觸情緒。儘管對有效治療方法的需求依然迫切，但這些安全問題仍然使治療格局變得複雜。根據美國睡眠醫學會預測，到2024年，將有12%的美國人被診斷出患有慢性失眠，凸顯出龐大的患者群體亟需能夠有效平衡臨床療效和長期安全性的藥物治療方案。

市場促進因素

慢性失眠和睡眠障礙的日益普遍是推動全球失眠藥物市場擴張的主要動力。這種成長動能源自於高壓力的都市生活方式和不斷上升的合併精神健康問題，使得當行為改變不足以改善睡眠時，醫療介入變得不可或缺。隨著睡眠不足演變為公共衛生危機，處方藥的目標族群也從暫時性失眠患者擴展到有慢性臨床需求的患者。 RiskStrategies 於 2025 年 6 月發布的關於失眠經濟負擔的報告估計，慢性失眠將影響 10% 至 15% 的普通人群，從而產生持續的需求。因此，醫療保健提供者必須將睡眠問題作為慢性病管理的重要組成部分。

新型藥物，特別是雙Orexin受體拮抗劑（DORA）的研發進展，是推動市場成長要素，促使市場轉向更安全、成癮性更低的治療方法。這些治療方法透過抑制覺醒路徑而非誘導全身鎮靜，解決了傳統藥物成癮和認知障礙等問題。這種轉變帶來了顯著的財務效益。例如，Eisai在2025年5月的財務報告中披露，其失眠治療藥物Devigo的銷售額達到538億日圓。同樣，Idolsia公司宣布，其產品在2025年第一季獲得了超過1,000萬張睡眠處方，顯示患者對這些創新作用機制的接受度很高。

市場挑戰

長期使用鎮靜劑帶來的安全隱患和依賴風險是全球失眠藥物市場成長的主要障礙。這些問題需要嚴格的監管，增加了藥物研發和市場核准的成本和複雜性。監管機構通常要求在鎮靜劑和催眠藥上標註嚴格的警告標籤，並限制處方指南，迫使醫療服務提供者縮短治療療程。因此，醫生往往優先考慮短期緩解症狀而非長期治療，以最大限度地降低依賴風險，從而導致重複處方減少。

此外，頻繁出現的不良反應會導致患者猶豫是否繼續治療，從而降低用藥依從性，並限制潛在益處。出現功能障礙的患者更有可能停止用藥。根據2024年睡眠基金會的數據，79%使用處方助眠藥物的成年人報告稱，第二天會出現嗜睡、困倦和注意力難以集中等殘留症狀。如此高的不利事件發生率加劇了消費者的疑慮，限制了藥物療法的推廣，最終阻礙了該行業的商業性擴張。

市場趨勢

選擇性Orexin-2受體拮抗劑（SORA）的臨床發展標誌著精準醫療的轉變，這與現有雙重Orexin受體拮抗劑更廣泛的作用機制截然不同。與目前旨在抑制整體覺醒的療法不同，這些新一代藥物針對特定的受體亞型，從而能夠針對複雜的表現型（包括合併精神疾病的患者）進行個人化治療。這種方法旨在將療效與不良的鎮靜作用區分開來，滿足那些對標準抗憂鬱症無反應的患者群體的需求。強生公司在2024年5月的新聞稿中強調了此類專業介入措施的必要性，指出約60%的重度憂鬱症（MDD）患者存在殘餘性失眠。

同時，藥物治療與處方數位療法的整合正在改變市場格局，創造出融合藥物治療和行為療法軟體的混合護理模式。這一趨勢透過使用FDA批准的數位工具作為第一線或輔助性治療，降低了安全隱患，同時減少了對高劑量、長期鎮靜劑的依賴，並促進了患者參與治療。真實世界數據支持了這個多面向策略的有效性。根據Knox Medical在2024年6月舉行的SLEEP 2024會議上發表的一項分析，在超過1500名患者中，數位認知行為療法（dCBT-I）的依從性達到了58%，證實了將數位解決方案與傳統藥物治療相結合的潛力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：失眠藥物治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依藥物類型（非處方藥、非處方助眠藥、非處方睡眠補充劑、處方藥）
    • 治療方法（非處方助眠藥、處方助眠藥）
    • 分銷通路（藥局、電子商務、醫​​院藥局、零售藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美失眠藥物治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲失眠藥物治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區失眠藥物治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲失眠藥物治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲失眠藥物治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球失眠藥物治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Merck & Co Inc
  • Ebb Therapeutics Inc/US
  • Pfizer Inc
  • Sanofi SA
  • Takeda Pharmaceutical Co Ltd
  • Paratek Pharmaceuticals Inc
  • Electromedical Products International Inc
  • Meda Pharmaceuticals Inc
  • Purdue Pharma LP
  • Pernix Therapeutics Holdings Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19003

The Global Insomnia Pharmacological Treatment Market is projected to expand from USD 4.03 Billion in 2025 to USD 5.63 Billion by 2031, reflecting a CAGR of 5.73%. This sector comprises a diverse array of prescription and over-the-counter medications, such as benzodiazepines, non-benzodiazepines, orexin receptor antagonists, and melatonin agonists, all aimed at facilitating sleep onset or maintenance. Growth is primarily fueled by the rising global incidence of sleep disorders resulting from high-stress modern living and an aging population prone to circadian rhythm issues. Additionally, rising healthcare spending and a fundamental cultural shift viewing sleep hygiene as essential to preventative health serve as enduring drivers for the industry.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.03 Billion
Market Size 2031USD 5.63 Billion
CAGR 2026-20315.73%
Fastest Growing SegmentOTC Sleep Supplements
Largest MarketNorth America

Despite these positive growth trajectories, the market encounters substantial obstacles related to safety concerns and the potential for dependency with long-term sedative use, which necessitate stringent regulations and cause patient reluctance. These safety issues complicate the therapeutic landscape even though the demand for effective treatments remains critical. According to the American Academy of Sleep Medicine, 12% of Americans reported a diagnosis of chronic insomnia in 2024, underscoring the significant population requiring pharmacological solutions that effectively balance clinical efficacy with long-term safety profiles.

Market Driver

The increasing prevalence of chronic insomnia and sleep disorders acts as the primary catalyst for the expansion of the Global Insomnia Pharmacological Treatment Market. This momentum is driven by the convergence of high-stress urban lifestyles and rising rates of mental health comorbidities, creating a need for medical intervention when behavioral changes fail. As sleep deprivation escalates into a public health crisis, the target demographic for prescription therapies has broadened from transient sufferers to those with chronic clinical needs. A June 2025 report by Risk Strategies on the economic burden of insomnia estimates that chronic insomnia affects 10-15% of the general population, creating sustained demand that compels healthcare providers to treat sleep issues as a vital part of chronic disease management.

Advancements in novel drug classes, particularly dual orexin receptor antagonists (DORAs), represent a second major growth factor by moving the market toward safer, non-habit-forming treatments. These therapies inhibit wakefulness pathways rather than inducing generalized sedation, addressing historical concerns regarding dependency and cognitive impairment. This shift is generating significant financial results; for instance, Eisai Co., Ltd. reported 53.8 billion yen in revenue for its insomnia treatment, Dayvigo, in their May 2025 financial report. Similarly, Idorsia noted in 2025 that over 10 million nights of sleep were prescribed for their product in the first quarter, demonstrating robust patient uptake of these innovative mechanisms.

Market Challenge

Safety concerns and the risk of dependency linked to long-term sedative use present a major obstacle to the growth of the Global Insomnia Pharmacological Treatment Market. These issues necessitate rigorous regulatory oversight, which escalates the cost and complexity associated with drug development and market approval. Authorities often enforce strict warning labels and limit prescribing guidelines for sedative-hypnotics, forcing healthcare providers to restrict the duration of therapy. Consequently, the volume of repeat prescriptions declines as physicians prioritize short-term symptom relief over long-term management to minimize addiction risks.

Furthermore, the frequency of adverse side effects generates significant patient hesitancy and lowers treatment adherence, thereby limiting revenue potential. Patients experiencing functional impairment are prone to discontinuing medication; data from the Sleep Foundation in 2024 indicates that 79% of adults using prescription sleep aids reported residual effects such as oversleeping, grogginess, or difficulty concentrating the following day. This high incidence of negative outcomes reinforces skepticism among consumers and restricts the widespread adoption of pharmacological interventions, ultimately hindering the sector's commercial expansion.

Market Trends

The clinical evolution of Selective Orexin-2 Receptor Antagonists (SORAs) marks a shift toward precision medicine, distinguishing itself from the broader mechanism of existing dual orexin receptor antagonists. Unlike current therapies that generally suppress wakefulness, this next-generation class targets specific receptor subtypes to tailor treatments for complex phenotypes, including patients with psychiatric comorbidities. This approach aims to separate efficacy from unwanted sedation, filling a gap for those unresponsive to standard antidepressants. Highlighting the need for such specialized interventions, a May 2024 press release from Johnson & Johnson noted that approximately 60% of patients with Major Depressive Disorder (MDD) suffer from residual insomnia symptoms.

Simultaneously, the integration of pharmacotherapy with prescription digital therapeutics is transforming the market by creating hybrid care models that blend medicinal treatments with behavioral software. This trend mitigates safety concerns by employing FDA-cleared digital tools as either first-line or complementary therapies, which helps reduce reliance on high-dose, long-term sedatives while enhancing patient engagement. Real-world data supports the viability of this multimodal strategy; a June 2024 analysis presented by Nox Medical at the SLEEP 2024 conference revealed a 58% adherence rate to digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) among over 1,500 patients, confirming the feasibility of combining digital solutions with traditional medication.

Key Market Players

  • Merck & Co Inc
  • Ebb Therapeutics Inc/US
  • Pfizer Inc
  • Sanofi SA
  • Takeda Pharmaceutical Co Ltd
  • Paratek Pharmaceuticals Inc
  • Electromedical Products International Inc
  • Meda Pharmaceuticals Inc
  • Purdue Pharma LP
  • Pernix Therapeutics Holdings Inc

Report Scope

In this report, the Global Insomnia Pharmacological Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Insomnia Pharmacological Treatment Market, By Drug

  • OTC Drugs
  • OTC Sleep Aids
  • OTC Sleep Supplements
  • Prescription Drugs

Insomnia Pharmacological Treatment Market, By Treatment

  • Over-the-Counter Sleep Aids
  • Prescription Sleep Aids

Insomnia Pharmacological Treatment Market, By Distribution Channel

  • Drug Stores
  • E-Commerce
  • Hospital Pharmacies
  • Retail Pharmacies

Insomnia Pharmacological Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Insomnia Pharmacological Treatment Market.

Available Customizations:

Global Insomnia Pharmacological Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Insomnia Pharmacological Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug (OTC Drugs, OTC Sleep Aids, OTC Sleep Supplements, Prescription Drugs)
    • 5.2.2. By Treatment (Over-the-Counter Sleep Aids, Prescription Sleep Aids)
    • 5.2.3. By Distribution Channel (Drug Stores, E-Commerce, Hospital Pharmacies, Retail Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Insomnia Pharmacological Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug
    • 6.2.2. By Treatment
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Insomnia Pharmacological Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Insomnia Pharmacological Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Insomnia Pharmacological Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By Distribution Channel

7. Europe Insomnia Pharmacological Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug
    • 7.2.2. By Treatment
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Insomnia Pharmacological Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Insomnia Pharmacological Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Insomnia Pharmacological Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Insomnia Pharmacological Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug
        • 7.3.4.2.2. By Treatment
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Insomnia Pharmacological Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug
        • 7.3.5.2.2. By Treatment
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Insomnia Pharmacological Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug
    • 8.2.2. By Treatment
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Insomnia Pharmacological Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Insomnia Pharmacological Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Insomnia Pharmacological Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Insomnia Pharmacological Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Insomnia Pharmacological Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Insomnia Pharmacological Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug
    • 9.2.2. By Treatment
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Insomnia Pharmacological Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Insomnia Pharmacological Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Insomnia Pharmacological Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Distribution Channel

10. South America Insomnia Pharmacological Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug
    • 10.2.2. By Treatment
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Insomnia Pharmacological Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Insomnia Pharmacological Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Insomnia Pharmacological Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Insomnia Pharmacological Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck & Co Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Ebb Therapeutics Inc/US
  • 15.3. Pfizer Inc
  • 15.4. Sanofi SA
  • 15.5. Takeda Pharmaceutical Co Ltd
  • 15.6. Paratek Pharmaceuticals Inc
  • 15.7. Electromedical Products International Inc
  • 15.8. Meda Pharmaceuticals Inc
  • 15.9. Purdue Pharma LP
  • 15.10. Pernix Therapeutics Holdings Inc

16. Strategic Recommendations

17. About Us & Disclaimer